## CORRECTION Open Access

## Correction: A synthetic cell-penetrating peptide derived from nuclear localization signal of EPS8 exerts anticancer activity against acute myeloid leukemia

Yiran Chen<sup>†</sup>, Xiaoling Xie<sup>†</sup>, Angin Wu, Lei Wang, Yuxing Hu, Honghao Zhang and Yuhua Li<sup>\*</sup>

Correction: J Exp Clin Cancer Res 37, 12 (2018) https://doi.org/10.1186/s13046-018-0682-x

Following publication of the original article [1], an error was identified in Fig. 7; specifically:

• Figure 7f: slice (PBS-4) was occupied by a duplicate slice (PBS-6); the correct image is now used.

The correction does not have any effect on the results or conclusions of the paper.

Published online: 30 July 2022

## Reference

 Chen Y, Xie X, Wu A, et al. A synthetic cell-penetrating peptide derived from nuclear localization signal of EPS8 exerts anticancer activity against acute myeloid leukemia. J Exp Clin Cancer Res. 2018;37:12. https://doi. org/10.1186/s13046-018-0682-x.

The original article can be found online at https://doi.org/10.1186/s13046-018-0682-x

<sup>†</sup>Yiran Chen and Xiaoling Xie are co-first authors.


\*Correspondence: liyuhua1974@outlook.com

Department of Hematology, Zhujiang Hospital, Southern Medical University, No. 253 GongyeDadaoZhong, Guangzhou, Guangdong 510282, People's Republic of China



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/loublicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data

Chen et al. J Exp Clin Cancer Res (2022) 41:233 Page 2 of 2



**Fig. 7** Antitumor activity of CP-EPS8-NLS in a U937 xenograft model. **a** U937 cells (5 × 10<sup>6</sup> per flank) were injected into the right flank of mice. When the volume of tumors reached 100 mm<sup>3</sup>, the mice were randomly divided into two groups (7 mice in each group). Then, PBS or CP-EPS8-NLS were intraperitoneally injected into the mice every other day. **b** The volume of each tumor was measured every other day for 22 days. **c** Body weight of the mice. **d** The volume of each tumor was measured after tumor extraction from the mice at the experimental endpoint. **e** Image of tumors excised from mice after 22 days of treatment. **f** EPS8 and Ki67 in tumor tissues at the end of the experiments using IHC staining